Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

17. November 2020 16:27 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer

– COO Role is Key to Preparedness for NDA Filing and Commercial Launch –– Clayton Fletcher, Head of Business Development & Strategic Planning, to Retire – EXTON, Pa., Nov. 17, 2020 (GLOBE...
29. Oktober 2020 16:36 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update

EXTON, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended...
28. September 2020 08:45 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037

EXTON, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,772,907 (the ‘907...
15. September 2020 07:18 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020

Final data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presentedAbbVie to present a trial-in-progress poster of ABBV-368...
04. August 2020 16:10 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update

EXTON, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended...
15. Juli 2020 08:05 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million

EXTON, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with institutional investors providing for...
02. Juni 2020 08:15 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Preliminary Data From and Planned Continuation of the ILLUMINATE-206 Trial for the Treatment of Micro-Satellite Stable Colorectal Cancer

EXTON, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today announced preliminary data from the first 10 patients in the safety cohort of ...
01. Mai 2020 08:00 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Change of Location for 2020 Annual Meeting of Stockholders

EXTON, Pa., May 01, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today provided notice of a change in the location for its 2020 Annual Meeting of...
30. April 2020 16:35 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update

EXTON, Pa., April 30, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended...
23. April 2020 07:30 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Tilsotolimod Program Updates to be Presented at AACR Virtual Annual Meeting 2020

EXTON, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA) today announced that updates on ILLUMINATE-206 and ILLUMINATE-101, two studies investigating...

Vorherige Seite